Company: RPTX
Filing Date: 2025-02-25
Form Type: 8-K
Source: 0001193125-25-033718
Chunk: 1

Company: Repare Therapeutics Inc.
Filing Date: 2025-02-25
Form: 8-K
Item: Item 5.02
Chunk 1
---
Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Medical Officer

In connection with the Reorganization described under Item 2.05 above, Dr. Maria Koehler, the Company’s Executive Vice-President, Chief Medical Officer, will cease her employment with the Company effective March 31, 2025 (the “ Separation Date”).

In connection with her departure, the Company expects to enter into a separation agreement with Dr. Koehler, pursuant to which the Company will provide Dr. Koehler with certain severance-related benefits, including (i) a lump sum payment equal to nine months of her current base salary, (ii) contingent upon her continuous service with the Company through the Separation Date, an additional cash payment of $150,000, (iii) contingent upon her providing consulting services for three months following the Separation Date, an additional cash payment of $86,250, (iv) continued payment by the Company of COBRA health insurance premiums for up to 12 months following the Separation Date, (v) nine months of vesting acceleration of all of her unvested and outstanding equity awards from the Separation Date and (vi) contingent upon a Change in Control (as defined in the Repare Therapeutics Inc. 2020 Equity Incentive Plan) within three months after the expiration of the consulting term, then in lieu of the separation benefits described above, Dr. Koehler shall be entitled to the Change in Control severance benefits provided pursuant to Section 5.7 of her Employment Agreement, a copy of which was filed as exhibit 10.10 to the Company’s Annual Report on Form10-Kfor the year ended December 31, 2023.

Retention Bonuses to Executive Officers

As noted above, in connect with Reorganization, the Company is paying retention cash bonuses to certain of its employees, including Steve Forte, its Executive Vice President, Chief Financial Officer, and Mike Zinda, its Executive Vice President, Chief Scientific Officer. Mr. Forte will receive a one-timecash retention payment of $175,000 and Dr. Zinda will receive a one-timecash retention payment of $150,000.